Advances in Medical Treatment of Primary Aldosteronism.
- Author:
Ying-Jie LI
1
;
Zhi-Gang JI
1
;
Jin WEN
1
Author Information
- Publication Type:Journal Article
- Keywords: aldosterone synthase inhibitors; calcium channel blockers; macrolide antibiotics; mineralocorticoid receptor antagonists; primary aldosteronism
- MeSH: Humans; Hyperaldosteronism/complications*; Adrenalectomy/adverse effects*; Aldosterone/therapeutic use*; Hypertension/drug therapy*; Mineralocorticoid Receptor Antagonists/therapeutic use*
- From: Chinese Medical Sciences Journal 2023;38(1):49-56
- CountryChina
- Language:English
- Abstract: Primary aldosteronism (PA) is the most common form of secondary hypertension, with its main manifestations including hypertension and hypokalemia. Early identification of PA is extremely important as PA patients can easily develop cardiovascular complications such as atrial fibrillation, stroke, and myocardial infarction. The past decade has witnessed the rapid advances in the genetics of PA, which has shed new light on PA treatment. While surgery is the first choice for unilateral diseases, bilateral lesions can be treated with mineralocorticoid receptor antagonists (MRAs). The next-generation non-steroidal MRAs are under investigations. New medications including calcium channel blockers, macrophage antibiotics, and aldosterone synthase inhibitors have provided a new perspective for the medical treatment of PA.
